All News

21 January 2011

Immunomedics Reports Targeted Therapy for Advanced Pancreatic Cancer Improves SurvivalAntibodies

21 January 2011

YM BioSciences Announces Data from Nimotuzumab Phase II Gastric Cancer Trial Reported at ASCO GI SymposiumAntibodies

21 January 2011

FibroGen Reports Interim Results of a Phase 1 / 2 Trial of FG-3019 in Locally Advanced or Metastatic Pancreatic CancerAntibodies

21 January 2011

NewLink Genetics to Present Phase 2 Data of Its HyperAcute Pancreas Immunotherapy at ASCO 2011 Gastrointestinal Cancers SymposiumAntibodies

20 January 2011

Investigational Compound Offers Novel Anti-IGF Approach To Inhibit Growth of Cancer CellsAntibodies

19 January 2011

Theraclone and Pfizer Enter into Infectious Disease and Cancer Antibody Discovery CollaborationAntibodies

19 January 2011

Merck Serono: Erbitux Long-Term Survival Benefit for mCRC Patients Confirmed With FOLFOXAntibodies

19 January 2011

Peregrine Announces Initiation of Investigator-Sponsored Trial in HER2-Negative Metastatic Breast CancerAntibodies

18 January 2011

MENTRIK Biotech, LLC Acquires Fc Engineered, High Affinity, Fully Humanized Anti-CD20 Antibody (AME-133v)Antibodies

18 January 2011

Regeneron and Bayer Start Phase 3 Trial to Extend Ophthalmology Research & Development Program for VEGF Trap-Eye in AsiaAntibodies

17 January 2011

DiaMedica Announces New Data With Its Novel Monoclonal Antibody ProgramAntibodies

12 January 2011

Sandoz announces phase II clinical trial for biosimilar version of leading monoclonal antibody rituximabAntibodies

12 January 2011

FibroGen Announces the Initiation of an Open-label Phase 2 Study to Evaluate the Safety and Efficacy of FG-3019 in Individuals with Idiopathic Pulmonary FibrosisAntibodies

12 January 2011

MedImmune and Micromet Announce Initiation of Phase 1 Trial of the CEA BiTE Antibody MEDI-565 (MT111) in Patients with Advanced Gastrointestinal CancersAntibodies

12 January 2011

MEDIMMUNE IN-LICENSES CLINICAL-STAGE ANTI-INFLAMMATORY MONOCLONAL ANTIBODY FROM AMGENAntibodies

11 January 2011

Enobia Announces Successful Completion of Phase II Juvenile Study of ENB-0040, a Bone Targeted Enzyme Replacement TherapyAntibodies

10 January 2011

Peregrine Initiates Randomized Phase II Trial of Bavituximab in Chronic Hepatitis CAntibodies

10 January 2011

OncoMed Pharmaceuticals Initiates Phase 1 Clinical Trial of Anti-Cancer Stem Cell Therapeutic OMP-59R5Antibodies

10 January 2011

Ablynx Provides Update on Its Ongoing Phase I Study for ALX-0141Antibodies

7 January 2011

Interim Three Month Data From Ongoing Six Month XOMA 052 Phase 2a Trial Support Safety and Biological ActivityAntibodies

7 January 2011

Immutep and GlaxoSmithKline sign licence agreement for IMP731Antibodies

7 January 2011

Helix BioPharma Corp. Files IND for a U.S. Phase I Clinical Study of Its Cancer Drug Candidate L-DOS47Antibodies

7 January 2011

Amgen and Xencor Enter Option Deal to Co-Develop Xencor’s Novel Antibody for Autoimmune DiseasesAntibodies

6 January 2011

MacroGenics Initiates Phase I Clinical Trial of MGAH22 for Patients With HER2-Expressing Solid TumorsAntibodies

6 January 2011

Spirogen Ltd. Announces a Research Collaboration and License Agreement With Genentech for the Discovery and Development of Antibody Drug ConjugatesAntibodies

6 January 2011

Mercator Therapeutics and X-BODY BioSciences Establish Alliance to Generate Antibody Cancer TherapeuticsAntibodies

6 January 2011

Seattle Genetics Announces Antibody-Drug Conjugate Collaboration with PfizerAntibodies

5 January 2011

arGEN-X Signs Discovery and Development Alliance With LillyAntibodies

5 January 2011

Ovatech To Present At “OneMedForum 2011” On the Heels of Completing Phase 2 Clinical Trial Of Ovaprene Non-Hormonal Intravaginal Contraceptive RingAntibodies

5 January 2011

FDA Grants Supplemental Approval for ACTEMRA® (tocilizumab)Antibodies

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

Competitor Analysis: Complement C5 Inhibitors & C5 Receptor Antagonists

Blockbuster Biologics 2018: Sales of Recombinant Therapeutic Antibodies & Proteins

Antibody Target, Technology & Pipeline Database: 1-Year Subscription

Intracellular Targets made druggable by TCR-like Antibodies, TCR Fusion Proteins & Cell-Penetrating Biologics 2018: an industry analysis of technologies, stakeholders, deals & trends

CD40 Agonists & CD40/L Antagonists Pipeline Review

Denosumab (Prolia & Xgeva) Biosimilars Pipeline Review

Folate Receptor alpha (FRα) Targeted Therapy Pipeline Review

Claudin 6, Cadherin 17, ROR1 and GPRC5D-Targeted Therapies: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

Eculizumab (Soliris) Biosimilars & Biosuperiors Pipeline Review

FcRn Inhibitors Pipeline Review